Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC [Phase 2]

View source ↗

Summary

Phase II trial evaluating HLX43 plus serplulimab as neoadjuvant therapy for non-small cell lung cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLX43
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING